Revolo Biotherapeutics Announces the Appointment of Tunde Otulana, M.D., to its Board of Directors

Revolo Biotherapeutics, a Company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, announced the appointment of industry veteran Tunde Otulana, M.D., to its Board of Directors. Dr. Otulana brings more than 25 years of leadership, clinical development and regulatory strategy experience in the life sciences industry.

“We are delighted to welcome Dr. Otulana’s expertise to our board of directors,” said Jonathan Rigby, Group Chief Executive Officer of Revolo Biotherapeutics. “His extensive experience in executive leadership, clinical development, and regulatory strategy particularly around allergic and pulmonary diseases will be extremely valuable as we advance our lead candidates, ‘1104 and ‘1805, through four Phase 2 clinical trials in 2022 and 2023 with the goal of revolutionizing autoimmune and allergic disease treatment.”

HR Technology News: 70% HRS Cite Flexibility of Work as the Topmost Reason for Resignations: GoodFirms Survey 2021


Dr. Otulana added, “I am honored to be joining Revolo’s board of directors and provide my expertise to advance revolutionary treatments with a unique mechanism of action for resetting the immune system from a pro-inflammatory state to a regulated homeostatic state. Revolo’s therapies have the potential to provide long-term disease remission for patients suffering from autoimmune and allergic diseases, who currently rely on chronic treatments that can suppress the immune system making patients vulnerable to life threatening infections and even cancer. I look forward to offering additional perspective on clinical and regulatory strategy as well, as the company advances four Phase 2 trials next year.”

Tunde Otulana, M.D., brings more than 25 years of combined experience in drug development and commercialization having served in multiple executive positions at several pharmaceutical companies, and currently as Chief Medical Officer at Veloxis Pharmaceuticals. Dr. Otulana also currently holds a Non-Executive Director position at Allergy Therapeutics, and is a Clinical Professor of Medicine, Pulmonary & Critical Care at the University of California, Davis, School of Medicine, where he has served for 22 years. Previously, Dr. Otulana served as Senior Vice President and Chief Medical Officer at several companies including Mallinckrodt Pharmaceuticals, Boehringer Ingelheim, and Aradigm Corporation. Notably, he served as Medical Officer and Medical Team Leader in the Pulmonary & Allergy Drug Products Division at the United States Food and Drug Administration (FDA) for about 7 years. Dr. Otulana received his medical degree from the University of Ibadan in Nigeria and completed residency and fellowship trainings in the UK and US.

HR Technology News: The Great Hiring Bounceback Continues: Employers Globally Report Optimistic Employment Outlooks for Q1 2022

[To share your insights with us, please write to]